Artificial Intelligence (AI) continues to be in the news in the Intellectual Property world.In a recent development in the UK, a decision to refuse an AI patent application was heard at appeal by the UK High Court. Interestingly, the appellant was unrepresented at the High Court hearing the judgement was remotely handed down on 22 January 2021.
Insights: patent application
Your engineers have been working on an exciting innovation. Their ideas have been developed in secret, and now they are ready for testing, which presents the issue of how to keep these new ideas secret. In the renewable energy sector, machines can be BIG. Consider GE’s Haliade X. This offshore wind turbine is 260 metres tall, and its rotor alone measures 220 metres. How do you test something like this in private?
For over 50 years the MacRobert Award has been recognising world-leading engineering innovations developed in the UK. Originally founded by the MacRobert Trust in 1969, the award has since become the UK’s longest-running and most coveted prize for UK engineering ingenuity. The annual award is now run by the Royal Academy of Engineering, and honours engineering achievements that demonstrate outstanding innovation, tangible societal benefit and proven commercial success. The list of past winners of the award serves as an impressive reminder of the wide-ranging capabilities of British engineers.
On Wednesday 15th January 2020, US president Donald Trump and Chinese vice-premier Liu He signed an economic and trade agreement which Mr Trump described as “the biggest deal anybody has even seen”. The deal promises to be the first phase of a larger new trade agreement between the US and China, signifying a de-escalation in their trade war – at least for now. Intellectual property (IP) was one of the main points of contention during the trade talks and thus it is perhaps unsurprising that IP matters are addressed in the first chapter. Of particular interest to those in the pharmaceutical sector will be Sections C and D of Chapter 1, which outline China’s commitment to improving protection and enforcement of pharmaceutical related patent rights. Sceptics will argue that these provisions simply represent a long overdue pledge by China to align its patent system with the US and other Western states, with no guarantee that they will actually implement or enforce the provisions of the agreement. However, in my view the deal appears to represent China’s willingness to do more to protect pharmaceutical patent rights and contains provisions that (if properly implemented and enforced) could significantly increase the value of drug related patents in China.
The World Intellectual Property Organization (WIPO) has recently released its annual review of patent applications filed under the Patent Cooperation Treaty (PCT). The report shows that approximately 253,000 PCT applications were filed in 2018. This is an increase of 3.9% from 2017, and it represents a ninth consecutive year of growth. PCT applications are clearly an increasingly popular choice for applicants seeking worldwide patent protection.